Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29790446 | 1.00 | KMT2A (0.61) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL2168383 | 1.00 | KMT2A (0.61) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL6261277 | 0.91 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL2167853 | 0.88 | KMT2A (0.60) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL25834661 | 0.88 | KMT2A (0.60) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL23702539 | 0.87 | KMT2A (0.58) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL17162091 | 0.87 | KMT2A (0.58) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL2169473 | 0.86 | TNF (0.50) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL6258804 | 0.86 | KMT2A (0.57) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL5025856 | 0.86 | KMT2A (0.57) | KMT2AMEN1ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266514-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190040037-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYOGYSZERGYAR ZRT. (HU) | 2019-02-07 | — | — | US | disclosed |
| US-20180044318-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2018-02-15 | — | — | US | disclosed |
| US-9822093-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017134476-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2017-08-10 | — | — | WO | disclosed |
| US-20160297791-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2016-10-13 | — | — | US | disclosed |
| US-9394274-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140256950-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| US-8785644-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2380887-B1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORP (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2380887-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | Celgene Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110224440-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7994327-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110104144-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
| EP-1965793-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1907373-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007079182-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155791-A1 | Methods for treating cutaneous lupus using aminoisoindoline compounds | CELGENE CORPORATION | 2007-07-05 | — | — | US | disclosed |
| WO-2007005972-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004920-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION AN ORGNIZATION OF THE STATE NEW JERSEY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155791-A1 | Methods for treating cutaneous lupus using aminoisoindoline compounds | SSB, ARG2, ARGLU1 | KMT2A 1411/4885MEN1 4097/4885ALDH1A1 2386/4885 |
| US-20110224440-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | KMT2A 3715/4885MEN1 4003/4885ALDH1A1 245/4885 |
| US-20110104144-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | SSB, ARG2, ARGLU1 | KMT2A 1411/4885MEN1 4097/4885ALDH1A1 2386/4885 |
| US-20160297791-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | KMT2A 3715/4885MEN1 4003/4885ALDH1A1 245/4885 |
| US-10266514-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | TNF, TRAF2, IL1A | KMT2A 3715/4885MEN1 4003/4885ALDH1A1 245/4885 |
| US-20190040037-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | PM20D2, HSD17B14, FUT5 | KMT2A 3693/4885MEN1 3831/4885ALDH1A1 1314/4885 |
| US-20070004920-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | TNF, DHPS, IL1A | KMT2A 3682/4885MEN1 3805/4885ALDH1A1 77/4885 |
| US-20140256950-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | KMT2A 3715/4885MEN1 4003/4885ALDH1A1 245/4885 |
| US-20180044318-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | KMT2A 3715/4885MEN1 4003/4885ALDH1A1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.